Rajendra P. Bandari

Harry S. Truman Memorial Veterans' Hospital — United States

Medicine · Health Sciences

9h-index240citations15works9.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Radiopharmaceutical Chemistry and Applications(10), Peptidase Inhibition and Analysis(6), Prostate Cancer Treatment and Research(5), Nanoparticle-Based Drug Delivery(2), Nanoplatforms for cancer theranostics(2)

Publications15 total

Bimodal MRI/Fluorescence Nanoparticle Imaging Contrast Agent Targeting Prostate Cancer
Nanomaterials·2024· 9 citedOpen Access
Development of Heterobivalent Theranostic Probes Having High Affinity/Selectivity for the GRPR/PSMA
Journal of Medicinal Chemistry·2021· 21 cited
Preclinical Evaluation of Novel <sup>64</sup>Cu-Labeled Gastrin-Releasing Peptide Receptor Bioconjugates for PET Imaging of Prostate Cancer
Bioconjugate Chemistry·2021· 10 cited
Development and Preclinical Evaluation of 99mTc- and 186Re-Labeled NOTA and NODAGA Bioconjugates Demonstrating Matched Pair Targeting of GRPR-Expressing Tumors
Molecular Imaging and Biology·2020· 18 cited
Design, Synthesis, and in Vitro and in Vivo Evaluation of High Affinity and Specificity Near-Infrared Fluorescent Bombesin Antagonists for Tumor Imaging
Journal of Medicinal Chemistry·2018· 18 cited
Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer
Nuclear Medicine and Biology·2018· 28 citedOpen Access
Synthesis and Evaluation of [DUPA-6-Ahx-Lys (DOTA)-6-Ahx-RM2], a Novel, Bivalent Targeting Ligand for GRPr/PSMA Biomarkers of Prostate Cancer
Chemical Biology Letters·2018· 2 citedOpen Access
In Vitro and In Vivo Evaluations of A High Affinity and Specificity Photoacoustic Nanoparticle Targeting to Cancer
2018
Molecular imaging investigations of a <sup>67</sup>Ga/<sup>64</sup>Cu labeledbivalent ligand, [RGD-Glu-(DO3A)-6-Ahx-RM2], targeting GRPR/<i>α</i> <sub> <i>v</i> </sub> <i>β</i> <sub>3</sub> biomarkers: a comparative study
Radiochimica Acta·2016· 5 cited
Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy
Current Radiopharmaceuticals·2015· 20 cited
Novel, multivalent tracers targeting prostate cancer biomarkers
Nuclear Medicine and Biology·2014
Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer
Nuclear Medicine and Biology·2014· 54 cited
A heterodimeric [RGD-Glu-[64Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors
Nuclear Medicine and Biology·2013· 40 citedOpen Access
Synthesis and Selective Radiolabeling Strategies for Production of [<sup>90</sup>Y-DOTA-βala-K-<sup>64</sup>Cu-NOTA-BBN(7–14) NH<sub>2</sub>] Conjugate; A Dual Negatron/Positron Emitting Radioligand
Synthesis and Reactivity in Inorganic Metal-Organic and Nano-Metal Chemistry·2012· 1 cited
Benign and malignant breast disease presenting to Bhaktapur Cancer Hospital.
PubMed·2007· 14 cited

Frequent Co-authors

Charles J. Smith(10), T. Reynolds(6), Zongrun Jiang(5), Ashley F. Szczodroski(3), Tammy L. Rold(3), Gary L. Sieckman(3), Yubin Miao(3), Charles J. Smith(3), Hang Xu(3), Lixin Ma(3), Timothy J. Hoffman(2), Jingli Xu(2), Michael R. Lewis(2), George Makris(2), Marina Kuchuk(2), Silvia S. Jurisson(2), Heather M. Hennkens(2), Ping Yu(2), Anita Sharma(2), Nicole E. Bernskoetter(1)